NeuroDex Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 14

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 9

NeuroDex General Information

Description

Developer of a blood-based diagnostics platform designed to diagnose neurodegenerative diseases. The company has developed neuron- and oligodendrocyte-derived extracellular vesicle isolation technologies, which are used to develop diagnostics for the leading indication of alpha-synuclein pathology, as well as for collaborations with life sciences companies and academia, enabling medical professionals to leverage advanced research in neurodegenerative diseases.

Contact Information

Website
www.neurodex.co
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 27 Strathmore Road
  • Natick, MA 01760
  • United States
+1 (609)
Primary Industry
Diagnostic Equipment
Vertical(s)
Corporate Office
  • 27 Strathmore Road
  • Natick, MA 01760
  • United States
+1 (609)

NeuroDex Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NeuroDex Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC 21-May-2024 Completed Generating Revenue
9. Grant 01-Jan-2024 Completed Generating Revenue
8. Later Stage VC 02-May-2023 Completed Generating Revenue
7. Grant 28-Mar-2023 Completed Generating Revenue
6. Grant 01-Jan-2023 Completed Product Development
5. Seed Round 22-Aug-2022 Completed Product Development
4. Grant 01-Jan-2022 Completed Startup
3. Seed Round 31-Jan-2020 Completed Startup
2. Grant 01-Jan-2019 $212K Completed Startup
1. Accelerator/Incubator Completed Startup
To view NeuroDex’s complete valuation and funding history, request access »

NeuroDex Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed 1
Seed
To view NeuroDex’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

NeuroDex Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a blood-based diagnostics platform designed to diagnose neurodegenerative diseases. The company has develop
Diagnostic Equipment
Natick, MA
14 As of 2026

San Diego, CA

San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NeuroDex Competitors (2)

One of NeuroDex’s 2 competitors is Exosome Sciences, a Corporate Backed or Acquired company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Exosome Sciences Corporate Backed or Acquired San Diego, CA
Amprion (Biotechnology) Venture Capital-Backed San Francisco, CA
You’re viewing 2 of 2 competitors. Get the full list »

NeuroDex Patents

NeuroDex Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026035725-A1 Use of brain-derived exosomes in neurodegenerative diseases Pending 05-Aug-2024
CA-3241305-A1 Improved exosome profiling for therapy and diagnosis Pending 19-Dec-2021
EP-4449121-A1 Improved exosome profiling for therapy and diagnosis Pending 19-Dec-2021
EP-4449121-A4 Improved exosome profiling for therapy and diagnosis Pending 19-Dec-2021
US-20250093343-A1 Improved exosome profiling for therapy and diagnosis Pending 19-Dec-2021 G01N33/54333
To view NeuroDex’s complete patent history, request access »

NeuroDex Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NeuroDex Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
StartUp Health Venture Capital Minority
Alzheimers Drug Discovery Foundation Not-For-Profit Venture Capital
Angel (individual) Minority
Red Abbey Venture Partners Venture Capital Minority
U.S. Department of Health and Human Services Government
You’re viewing 5 of 9 investors. Get the full list »

NeuroDex FAQs

  • When was NeuroDex founded?

    NeuroDex was founded in 2018.

  • Where is NeuroDex headquartered?

    NeuroDex is headquartered in Natick, MA.

  • What is the size of NeuroDex?

    NeuroDex has 14 total employees.

  • What industry is NeuroDex in?

    NeuroDex’s primary industry is Diagnostic Equipment.

  • Is NeuroDex a private or public company?

    NeuroDex is a Private company.

  • What is NeuroDex’s current revenue?

    The current revenue for NeuroDex is .

  • How much funding has NeuroDex raised over time?

    NeuroDex has raised $1.66M.

  • Who are NeuroDex’s investors?

    StartUp Health, Alzheimers Drug Discovery Foundation, , Red Abbey Venture Partners, and U.S. Department of Health and Human Services are 5 of 9 investors who have invested in NeuroDex.

  • Who are NeuroDex’s competitors?

    Exosome Sciences and Amprion (Biotechnology) are competitors of NeuroDex.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process